49.20
price down icon1.49%   -0.70
 
loading
前日終値:
$49.90
開ける:
$50.25
24時間の取引高:
717.14K
Relative Volume:
0.34
時価総額:
$6.07B
収益:
$692.26M
当期純損益:
$-512.41M
株価収益率:
-11.60
EPS:
-4.24
ネットキャッシュフロー:
$-274.36M
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
+29.36%
6か月 パフォーマンス:
+56.69%
1年 パフォーマンス:
+67.25%
1日の値動き範囲:
Value
$48.07
$50.33
1週間の範囲:
Value
$47.45
$51.15
52週間の値動き範囲:
Value
$20.14
$52.92

Guardant Health Inc Stock (GH) Company Profile

Name
名前
Guardant Health Inc
Name
セクター
Healthcare (1171)
Name
電話
855-698-8887
Name
住所
3100 HANOVER STREET, PALO ALTO
Name
職員
2,021
Name
Twitter
@guardanthealth
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
GH's Discussions on Twitter

GH を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Diagnostics & Research icon
GH
Guardant Health Inc
49.20 6.07B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
411.30 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
201.78 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
527.97 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
119.38 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
157.64 27.64B 15.50B 1.33B 2.16B 7.34

Guardant Health Inc Stock (GH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-10 開始されました Mizuho Outperform
2025-01-23 開始されました Barclays Overweight
2024-06-28 アップグレード Guggenheim Neutral → Buy
2024-06-03 再開されました Jefferies Buy
2024-04-24 再開されました Craig Hallum Buy
2023-12-14 開始されました Guggenheim Neutral
2023-12-13 開始されました Wolfe Research Peer Perform
2023-11-13 アップグレード Raymond James Mkt Perform → Outperform
2023-09-28 開始されました Bernstein Outperform
2023-09-27 アップグレード Piper Sandler Neutral → Overweight
2023-07-05 再開されました JP Morgan Overweight
2023-05-26 アップグレード Citigroup Neutral → Buy
2023-05-05 開始されました UBS Buy
2023-03-09 ダウングレード Citigroup Buy → Neutral
2023-01-05 開始されました Scotiabank Sector Outperform
2022-11-01 ダウングレード Piper Sandler Overweight → Neutral
2022-10-19 開始されました Craig Hallum Buy
2022-10-06 開始されました Stephens Overweight
2022-08-25 開始されました Credit Suisse Outperform
2022-06-03 開始されました Piper Sandler Overweight
2022-04-28 再開されました BTIG Research Buy
2022-02-24 繰り返されました Canaccord Genuity Buy
2022-02-24 繰り返されました Citigroup Buy
2022-02-24 繰り返されました Cowen Outperform
2022-02-24 繰り返されました Morgan Stanley Overweight
2022-02-24 繰り返されました SVB Leerink Outperform
2022-02-24 繰り返されました Stifel Buy
2022-02-24 繰り返されました Wells Fargo Overweight
2021-10-15 再開されました Cowen Outperform
2021-06-15 開始されました Raymond James Mkt Perform
2021-06-03 開始されました Goldman Buy
2021-05-25 開始されました Wells Fargo Overweight
2021-01-11 開始されました Stifel Buy
2020-09-09 開始されました Morgan Stanley Overweight
2020-06-12 開始されました BTIG Research Buy
2020-02-21 開始されました Guggenheim Buy
2020-01-07 開始されました Citigroup Buy
2019-08-07 繰り返されました Canaccord Genuity Buy
2019-04-16 開始されました Canaccord Genuity Buy
2019-04-10 アップグレード BofA/Merrill Neutral → Buy
2019-02-28 繰り返されました BofA/Merrill Neutral
2018-10-29 開始されました BofA/Merrill Neutral
2018-10-29 開始されました JP Morgan Overweight
2018-10-29 開始されました William Blair Outperform
すべてを表示

Guardant Health Inc (GH) 最新ニュース

pulisher
Jun 18, 2025

Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing

Jun 18, 2025
pulisher
Jun 17, 2025

Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine

Jun 17, 2025
pulisher
Jun 16, 2025

Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health director sells shares worth $157,573 - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health Executives Sell Shares - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health (NASDAQ:GH) Given New $65.00 Price Target at Mizuho - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

(GH) Investment Report - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 13, 2025

Mizuho raises Guardant Health price target on positive Shield test outlook - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Guardant Health (GH) Price Target Raised to $65 by Mizuho | GH S - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.

Jun 12, 2025
pulisher
Jun 12, 2025

Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts - MarketBeat

Jun 12, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Aw - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening | GH Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility - The ASCO Post

Jun 10, 2025
pulisher
Jun 10, 2025

Insider Sell: Amirali Talasaz Sells 119,284 Shares of Guardant H - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Guardant Health Inc (GH) Shares Up 4.04% on Jun 9 - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Guardant Health at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Guardant Health, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - BioSpace

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer | GH Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 07, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | G - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Insider Sell: Kumud Kalia Sells 4,000 Shares of Guardant Health Inc (GH) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Inc (GH) Shares Up 3.5% on Jun 5 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Has $230,000 Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

Minimal Residual Disease Testing Market Set to Witness - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com

Jun 05, 2025
pulisher
Jun 04, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health gets FDA breakthrough device status for cancer detection test - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s MCD test earns FDA breakthrough designation - Yahoo

Jun 04, 2025
pulisher
Jun 04, 2025

111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s cancer test earns FDA breakthrough status By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Leerink Partners maintains outperform rating for Guardant Health stock By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Stock Surges on FDA Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Why Guardant Health Stock Surged Nearly 9% Higher Today - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

NCCN Adds 2 Tests to CRC Screening Guidelines - OncLive

Jun 03, 2025
pulisher
Jun 03, 2025

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?Guardant Health (NASDAQ:GH) - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Gains as FDA Grants Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health’s cancer test earns FDA breakthrough status - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus

Jun 03, 2025

Guardant Health Inc (GH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
diagnostics_research DGX
$176.48
price down icon 1.09%
diagnostics_research WAT
$352.40
price up icon 0.95%
diagnostics_research LH
$260.81
price up icon 0.75%
$165.11
price down icon 3.13%
diagnostics_research MTD
$1,173.51
price up icon 0.24%
diagnostics_research IQV
$158.54
price down icon 0.33%
大文字化:     |  ボリューム (24 時間):